Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics Plc (BRNS)
:BRNS
BRNS Stock Chart & Stats
$1.37
>-$0.01(-0.43%)
At close: 4:00 PM EST
$1.37
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.64 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)187.19K
Market Cap
$53.66M
Enterprise Value-$38.17M
Total Cash (Recent Filing)$86.26M
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 06, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding40,718,227
10 Day Avg. Volume52,045
30 Day Avg. Volume187,193
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.71
Enterprise Value/Revenue-2.55
Enterprise Value/Gross Profit32.66
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$3.00Price Target Upside118.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 1 trial of CLY-101 demonstrated safety and tolerability, supporting its potential use for Type 1 and Type 2 diabetes treatment.
Financial StabilityThe combined company is expected to be funded by existing cash and additional investments, providing financial stability through 2027.
Merger And AcquisitionThe merger between Barinthus Biotherapeutics and Clywedog Therapeutics adds valuable diabetes assets to the combined company.
Bears Say
Competitive LandscapeThe competitive landscape for celiac disease treatment includes major players like Sanofi and Teva, which are advancing their Phase 2 trials.
Financial Performance ConcernsThe net loss of $21.2M was significantly higher than the estimated loss of $11.8M, which could raise concerns about financial performance.
Stock ValuationBarinthus shares are trading at a negative enterprise value, when considering the two wholly owned programs.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics Plc’s price range in the past 12 months?
Barinthus Biotherapeutics Plc lowest stock price was $0.64 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics Plc’s market cap?
Barinthus Biotherapeutics Plc’s market cap is $53.66M.
When is Barinthus Biotherapeutics Plc’s upcoming earnings report date?
Barinthus Biotherapeutics Plc’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.
How were Barinthus Biotherapeutics Plc’s earnings last quarter?
Barinthus Biotherapeutics Plc released its earnings results on Aug 07, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.19.
Is Barinthus Biotherapeutics Plc overvalued?
According to Wall Street analysts Barinthus Biotherapeutics Plc’s price is currently Undervalued.
Does Barinthus Biotherapeutics Plc pay dividends?
Barinthus Biotherapeutics Plc does not currently pay dividends.
What is Barinthus Biotherapeutics Plc’s EPS estimate?
Barinthus Biotherapeutics Plc’s EPS estimate is -0.38.
How many shares outstanding does Barinthus Biotherapeutics Plc have?
Barinthus Biotherapeutics Plc has 40,718,227 shares outstanding.
What happened to Barinthus Biotherapeutics Plc’s price movement after its last earnings report?
Barinthus Biotherapeutics Plc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 10.687%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics Plc?
Currently, no hedge funds are holding shares in BRNS
Barinthus Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (118.98% Upside)
$3.00 (118.98% Upside)
Blogger Sentiment
Bullish
BRNS Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.76%
12-Months-Change
Fundamentals
Return on Equity
-53.78%
Trailing 12-Months
Asset Growth
-30.62%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics Plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$3.00
▲(118.98% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
3.50%
Insiders
0.03% Mutual Funds
22.09% Other Institutional Investors
74.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---